Dendreon Jumps 10%
Shares of Dendreon (NASDAQ: DNDN) were sold off hard on Monday after positive data was presented at the American Society of Clinical Oncology conference in Chicago over the weekend showing a high rate of efficacy for a Johnson & Johnson (NYSE: JNJ) prostrate cancer drug called Zytiga which is a competitor to DNDN's Provenge treatment. On Tuesday, however, Dendreon shares are bouncing back from the steep losses and were last trading up more than 10% to $6.54.
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.